Cure8 research brief
The work searches for shared blood-based gene signatures and biomarkers across HLA-B27–linked diseases (including Crohn’s disease and ulcerative colitis), which could point to common mechanisms or cross-disease diagnostic markers.
Researchers in IBD and spondyloarthritis, translational scientists studying biomarkers or shared immune pathways, and clinicians with interest in molecular diagnostics for immune-mediated diseases.
The authors analyzed GEO transcriptomic datasets with differential expression, LASSO modeling, ROC filtering, PPI and pathway analyses, and constructed regulatory (ceRNA–TF) networks. They then validated selected gene expression by RT‑qPCR and Western blot in PBMCs from patients with ankylosing spondylitis (AS) and ulcerative colitis (UC).
ABCD2 emerged as the only gene shared across all five diseases in their analysis. The paper interprets these findings as exploratory candidates for further research rather than established clinical biomarkers.
This classification and note are grounded in the article abstract and reported experimental validation in PBMCs; results are exploratory and not yet clinical-grade biomarkers.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.
If hospital-treated infections raise later IBD risk—especially in people with certain immune-related genetic variants—this supports a multi-hit model of IBD and could eventually help identify higher-risk individuals...
This research suggests genetic risk scores could help identify people with IBD who are more likely to have severe disease, which might eventually inform earlier monitoring or treatment decisions. It’s a step toward more...
